Alexion has announced that four members of the company’s C-suite team are set to leave the company, following an internal investigation into sales practices.
Chief financial officer Dave Anderson is among the casualties, who while just joining the company this past December is set to resign in August. Alexion will also lose its R&D chief, Martin Mackay, to retirement. EVP and head of human resources Clare Carmichael and commercial chief Carsten Thiel are leaving as well, with Thiel’s replacement, Brian Goff, already hired.
Alexion has completely remade its executive makeup, which began when former CEO David Hallal lost investor confidence amid sales fraud investigations that demonstrated that the company inappropriately pressured staff to pad sales of its Soliris treatment.
> Read the Wall Street Journal report
Source: Pharmaceutical Manufacturing
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
